Author(s):
R. Padmavathi, Tulja Bhavani Munnam, Neha Tabassum, Sai Praneeth Kotte, Jawale Priyanka
Email(s):
gprcphyd@gmail.com
DOI:
10.52711/2231-5691.2025.00049 
Address:
R. Padmavathi, Tulja Bhavani Munnam*, Neha Tabassum*, Sai Praneeth Kotte, Jawale Priyanka
M. Pharmacy, G. Pulla Reddy College of Pharmacy, Osmania University, Mehdipatnam, Hyderabad, Telangana - 500028.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2025
ABSTRACT:
Alzheimer’s disease is a type of dementia commonly affecting older people. It is a age related neurodegenerative disorder characterized by multiple cognitive deficiencies which include memory loss, comprehensive. It causes mood disturbances and behavioral changes. 54% of dementia cases are believed to be due to Alzheimer disease in European union. There is no medicine discovered for Alzheimer’s but symptomatic therapies are widely available now. One of them is the therapy using Rivastigmine, it comes under the class of acetylcholinesterase inhibitors. Comparative analysis with other Cholinestrase inhibitors sheds light on the unique attributes of Rivastigmine. In this review Article we will be discussing about its background and history, pharmacokinetics and pharmacological parameters, physicochemical properties, method of synthesis, drug - drug interactions Special populations and many more.
Cite this article:
R. Padmavathi, Tulja Bhavani Munnam, Neha Tabassum, Sai Praneeth Kotte, Jawale Priyanka. Rivastigmine in Focus: A Key Player in Alzheimer Disease Management. Asian Journal of Pharmaceutical Research. 2025; 15(3):316-0. doi: 10.52711/2231-5691.2025.00049
Cite(Electronic):
R. Padmavathi, Tulja Bhavani Munnam, Neha Tabassum, Sai Praneeth Kotte, Jawale Priyanka. Rivastigmine in Focus: A Key Player in Alzheimer Disease Management. Asian Journal of Pharmaceutical Research. 2025; 15(3):316-0. doi: 10.52711/2231-5691.2025.00049 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2025-15-3-13
REFERENCES:
1. Farlow, M. R. Update on Rivastigmine. The Neurologist. 2003; 9(5): 230-234.
2. Kumar, V. Potential medicinal plants for CNS disorders: an overview. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2006; 20(12): 1023-1035.
3. Polinsky, R. J. Clinical pharmacology of Rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical Therapeutics. 1998; 20(4): 634-647.
4. Jann MW. Rivastigmine, a new‐generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2000 Jan; 20(1): 1-2.
5. Grossberg, G. T., Stahelin, H. B., Messina, J. C., Anand, R., & Veach, J., Lack of adverse pharmacodynamic drug interactions with Rivastigmine and twenty‐two classes of medications. International Journal of Geriatric Psychiatry. 2000; 15(3): 242-247.
6. Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, Cutler NR. Estimation of the absolute bioavailability of Rivastigmine in patients with mild to moderate dementia of the Alzheimer’s type. Clinical Pharmacokinetics. 2002 Mar; 41: 225-34.
7. Cass, S. P. Alzheimer’s disease and exercise: a literature review. Current Sports Medicine Reports. 2017; 16(1); 19-22
8. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007 Jul 24; 69(4_suppl_1): S14-22.
9. Pakala RS, Brown KN, Preuss CV. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL). 2023. Cholinergic Medications.
10. Kandiah, N., Pai, M. C., Senanarong, V., Looi, I., Ampil, E., Park, K. W. and Christopher, S. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clinical Interventions in Aging. 2017; 697-707.
11. National Center for Biotechnology InformationPubChem Compound Summary for CID 77991, Rivastigmine. Retrieved December 23, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/Rivastigmine.
12. Amaro, M. I., Simon, A., Cabral, L. M., de Sousa, V. P., & Healy, A. M. Rivastigmine hydrogen tartrate polymorphs: Solid-state characterisation of transition and polymorphic conversion via milling. Solid State Sciences. 2015; 49: 29-36.
13. Hu, M., Zhang, F. L., and Xie, M. H. Novel convenient synthesis of Rivastigmine. Synthetic Communications®. 2009; 39(9): 1527-1533.
14. Lovborg, H., K Jonsson, A., and Hagg, S. A fatal outcome after unintentional overdosing of Rivastigmine patches. Current drug Safety. 2012; 7(1): 30-32.
15. Williams, B. R., Nazarians, A., and Gill, M. A.A review of Rivastigmine: a reversible cholinesterase inhibitor. Clinical Therapeutics. 2003; 25(6): 1634-1653.
16. Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs and Aging. 2003 May; 20: 437-44.
17. Stanford University, Last Updated March 2024, Google patents, Accessed on April 4th 2024, URL: https://patents.google.com/patent/US9585862B2/en?oq=+US9585862B2++
18. Yoo JH, Valdovinos MG, Williams DC. Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. Journal of Autism and Developmental Disorders. 2007; 37: 1883-901.
19. Houry R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer’s disease: focus on Rivastigmine. Therapeutic Advances in Drug Safety. 2018; 9(3):171-8.
20. Design, Formulation and in vitro Drug Release from Transdermal Patches containing Nebivolol Hydrochloride as Model Drug. Asian J. Pharm. Res. 2012; 2(4): 136-141.